AbbVie notches Phase 3 win in painful skin condition, FDA filing likely next year
AbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease. In the trial, AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.